JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Want to see JP:4552 full AI Analyst Report?
4552 Stock Chart & Stats
¥712.00
-¥21.00(-3.43%)
At close: 4:00 PM EST
¥712.00
-¥21.00(-3.43%)
Day’s Range― - ―
52-Week Range¥445.00 - ¥824.00
Previous CloseN/A
Volume326.50K
Average Volume (3M)578.69K
Market Cap
¥57.30B
Enterprise Value¥100.52B
Total Cash (Recent Filing)¥13.18B
Total Debt (Recent Filing)¥40.10B
Price to Earnings (P/E)25.1
Beta0.88
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)-45.01
Shares Outstanding129,686,310
10 Day Avg. Volume668,090
30 Day Avg. Volume578,686
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)1.48
Price to Sales (P/S)1.72
P/FCF Ratio-5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥630.00Price Target Upside-11.52% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.33
Revenue Forecast (FY)¥42.87B
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Gross Margin ResilienceA durable revenue rebound (+20% in FY2026) alongside consistently strong gross profit indicates recovered end-market demand and a resilient product mix. Sustained gross margins underpin long-term profitability potential and support continued R&D and commercialization in specialty segments if operating leverage improves.
Sizable Equity Base And Stable AssetsA sizable equity base and stable asset base provide a structural buffer against shocks, supporting ongoing investment in biologics and manufacturing. This capital foundation improves solvency resilience, enabling the company to absorb temporary cash-flow volatility while pursuing medium-term strategic initiatives.
Specialty Biologics Focus And Manufacturing CapabilityConcentration on rare-disease biologics and contract manufacturing is a structural competitive advantage: higher barriers to entry, pricing leverage under reimbursement frameworks, and diversified revenue via manufacturing services. These elements support durable demand and margin opportunities over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow materially weakens internal funding for R&D, commercialization, and capex. Over 2–6 months this raises funding and execution risk, forcing reliance on external financing and potentially delaying strategic projects or squeezing liquidity during product rollouts.
Meaningfully Higher LeverageA sharp rise in debt reduces financial flexibility and increases interest and refinancing burdens. In combination with volatile profitability and weak cash flow, elevated leverage heightens the risk that the firm cannot fund operations or investments without costly external financing or strategic trade-offs.
Volatile Profitability Across YearsLarge year-to-year swings in operating results reduce predictability of earnings and cash generation. This undermines long-term planning for product launches and R&D, increases sensitivity to market setbacks, and makes consistent margin improvement and debt service more uncertain over the medium term.
JCR Pharmaceuticals Co., Ltd. News
4552 FAQ
What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥445.00 and its highest was ¥824.00 in the past 12 months.
What is JCR Pharmaceuticals Co., Ltd.’s market cap?
JCR Pharmaceuticals Co., Ltd.’s market cap is ¥57.30B.
When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is Jul 29, 2026 which is in 54 days.
How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?
JCR Pharmaceuticals Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥3.57 earnings per share for the quarter, beating the consensus estimate of -¥6.628 by ¥10.198.
Is JCR Pharmaceuticals Co., Ltd. overvalued?
According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Overvalued.
Does JCR Pharmaceuticals Co., Ltd. pay dividends?
JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 2.71%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here
What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?
JCR Pharmaceuticals Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?
JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.
What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥3.57 in its last earnings report, beating expectations of -¥6.628. Following the earnings report the stock price went up 0.896%.
Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
4552 Stock 12 Month Forecast
Average Price Target
¥630.00
▼(-11.52% Downside)
Technical Analysis
Kyowa Kirin Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---